China channel feed

Biose­cure law­mak­ers tell trade groups that Chi­na stud­ies are a new fo­cus

11 months ago
Deals

Chi­na cor­rup­tion crack­down hits Mer­ck’s Gar­dasil sales, spook­ing in­vestors

11 months ago
Pharma

WuXi AppTec sees US rev­enue de­cline amid Biose­cure threat

11 months ago
Manufacturing

BeiGene plots to fur­ther build its man­u­fac­tur­ing mus­cle out­side of Chi­na

11 months ago
Manufacturing

Chi­nese biotech de­vel­op­ing semaglu­tide biosim­i­lar files for Hong Kong IPO

11 months ago
Financing

WuXi AppTec more than tripled lob­by­ing spend as Biose­cure Act ad­vanced in Con­gress

11 months ago
Law

Chi­na ap­proves Eli Lil­ly's weight loss drug as coun­try launch­es obe­si­ty aware­ness cam­paign

11 months ago
Pharma

Or­biMed forms biotech with as­sets from Chi­na-based Keymed, en­lists for­mer Bio­haven ex­ec as CEO

11 months ago
Financing
Startups

Chi­nese drug­mak­ers still lag in R&D depth de­spite out­pac­ing Eu­ro­peans in new launch­es

Last year
R&D
Pharma

House speak­er plans vote on Biose­cure Act as part of Chi­na leg­is­la­tion push

Last year
Pharma

As con­fi­dence falls, bio­phar­ma com­pa­nies take pre­cau­tions with Chi­nese part­ner­ships, sur­vey finds

Last year
Outsourcing
Manufacturing

Com­mer­cial-stage blood can­cer biotech files for US dual list­ing

Last year
Financing

Day One en­ters ADC field, go­ing af­ter a tar­get that once at­tract­ed Ab­b­Vie and now Gen­mab

Last year
Deals

AI drug dis­cov­ery start­up goes pub­lic in Hong Kong, nab­bing $115M to build on phar­ma part­ner­ships

Last year
Financing
AI

Chi­na biotech ban does not make the cut as add-on to de­fense spend­ing bill

Last year
Law

BIO's new CEO takes a pa­tri­ot­ic piv­ot to win back Con­gress, push­ing in­dus­try to re­think Chi­na re­la­tion­ship

Last year
In Focus

FDA hands Chi­nese drug man­u­fac­tur­er a Form 483 not­ing em­ploy­ees de­stroyed doc­u­ments 

Last year
FDA+
Manufacturing

No­vo Hold­ings’ head of Asia on in­vest­ing in ‘Chi­na for Chi­na,’ and stay­ing out of biotech (for now)

Last year
Financing
Pharma

Up­dat­ed: With a promis­ing new Keytru­da con­tender, Sum­mit pre­pares to spar with Mer­ck

Last year
R&D
Pharma

Gen­Fleet high­lights Phase 2 da­ta on KRAS/EGFR com­bo in lung can­cer 

Last year
R&D

BioN­Tech dou­bles down on ADC part­ner MediLink in new $1.8B biobucks pact

Last year
Startups
Deals

Nu­va­tion Bio shares piv­otal Chi­na da­ta for can­cer drug from An­Heart buy­out

Last year
R&D

Mer­ck KGaA avoids pros­e­cu­tion af­ter co­op­er­at­ing with DOJ to un­cov­er Chi­na ex­port scheme

Last year
Law

Take­da en­ters hot mol­e­c­u­lar glue space in up to $1.2B pact with De­gron

Last year
Startups
Pharma
First page Previous page 3456789 Next page Last page
A service from the Financial Times